Tenecteplase Dosing and Management in STEMI and Pulmonary Embolism (Evidence‑Based)

Dosing Adjustments in Special Populations

Obesity (BMI ≥ 30 kg/m²): The tenecteplase dose is capped at 50 mg for patients weighing ≥ 90 kg; no further increase is recommended regardless of higher body weight. This ceiling dose is endorsed by the 2024 European Society of Cardiology consensus on antithrombotic therapy in obesity. 4
Elderly patients (≥ 75 years) when tenecteplase is used off‑label for acute ischemic stroke: Recommended dose is 0.25 mg/kg (maximum 25 mg); some guidelines suggest using half of the standard STEMI dose in this age group. 4
Avoid under‑dosing in obese patients: Capping the dose below 50 mg in patients > 90 kg reduces the likelihood of achieving arterial patency and should be avoided. 4

Standard‑risk adults (< 75 years) with normal renal function:
- Enoxaparin regimen: 30 mg IV bolus administered with or immediately after tenecteplase, followed by 1 mg/kg subcutaneously every 12 hours. (Class I recommendation, evidence level not specified). 6
Patients ≥ 75 years or with renal dysfunction:
- Unfractionated heparin (UFH) regimen: 60 U/kg IV bolus (maximum 4,000 U), then continuous infusion at 12 U/kg/h (maximum 1,000 U/h) targeting an activated partial thromboplastin time of 1.5–2.0 × control (≈ 50–70 seconds). (Class I recommendation, evidence level not specified). 5
Renal impairment considerations: When serum creatinine exceeds 2.5 mg/dL in men or 2.0 mg/dL in women, avoid enoxaparin as ancillary anticoagulation and use UFH instead. (Class I recommendation, evidence level not specified). [5][6]

Massive (hemodynamically unstable) PE: The FDA‑approved regimen is alteplase 100 mg infused over 2 hours. Tenecteplase at the standard STEMI weight‑adjusted doses (30–50 mg) has been used in clinical practice but remains off‑label. (Class IIb recommendation, evidence level not specified). 4

Monitoring interval: Assess ST‑segment resolution, cardiac rhythm, and symptoms 60–90 minutes after tenecteplase administration. (Class I recommendation, evidence level not specified). 5
Clinical indicators of successful reperfusion:
- Relief of chest pain. 6
- Hemodynamic and electrical stability. 6
- ≥ 50 % reduction in ST‑segment elevation on follow‑up ECG. (Class I recommendation, evidence level not specified). 5

All facts are derived from peer‑reviewed guidelines and clinical studies, with citation identifiers provided for reference.